Systematic review of drug therapy for chorea in NXK2 ‐1‐related disorders: Efficacy and safety evidence from case studies and series
European Journal of Neurology · 2023
DOI: 10.1111/ene.16038 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Neurology, 2023. Verfasst von Laia Nou-Fontanet und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Neurology, Hospital Sant Joan de Déu, Barcelona, Spain. Hauptthemen laut MEDLINE: Chorea, Methylphenidate. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
The NKX2‐1 ‐related disorders ( NKX2‐1 ‐RD) is a rare disorder characterized by choreiform movements along with respiratory and endocrine abnormalities. The European Reference Network of Rare Neurological Disorders funded by the European Commission conducted a systematic review to assess drug treatment of chorea in NKX2‐1 ‐RD, aiming to provide clinical recommendations for its management.
Methods
A systematic pairwise review using various databases, including MEDLINE, Embase, Cochrane, CINAHL, and PsycInfo, was conducted. The review included patients diagnosed with chorea and NKX2‐1 ‐RD genetic diagnosis, drug therapy as intervention, no comparator, and outcomes of chorea improvement and adverse events. The methodological quality of the studies was assessed, and the study protocol was registered in PROSPERO.
Results
Of the 1417 studies examined, 28 studies met the selection criteria, consisting of 68 patients. The studies reported 22 different treatments for chorea, including carbidopa/levodopa, tetrabenazine, clonazepam, methylphenidate, carbamazepine, topiramate, trihexyphenidyl, haloperidol, propranolol, risperidone, and valproate. No clinical improvements were observed with carbidopa/levodopa, tetrabenazine, or clonazepam, and various adverse effects were reported. However, most patients treated with methylphenidate experienced improvements in chorea and reported only a few negative effects. The quality of evidence was determined to be low.
Conclusions
The management of chorea in individuals with NKX2‐1 ‐RD presents significant heterogeneity and lack of clarity. While the available evidence suggests that methylphenidate may be effective in improving chorea symptoms, the findings should be interpreted with caution due to the limitations of the studies reviewed. Nonetheless, more rigorous and comprehensive studies are necessary to provide sufficient evidence for clinical recommendations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatric Neurology, Hospital Sant Joan de Déu, Barcelona, Spain.
- Health Technology Assessment Area-AETSA, Andalusian Public Foundation for Progress and Health ("Fundación Progreso y Salud"-"FPS"), Seville, Spain.
- Research Group HUM604: Lifestyle Development in the Life Cycle and Health Promotion, University of Huelva, Huelva, Spain.
- Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, National Center of Reference for Huntington's Disease, Créteil, France.
- Département d'Etudes Cognitives, École Normale Supérieure, PSL University, Paris, France.
- European Reference Network for Rare Neurological Diseases (ERN-RND), Tübingen, Germany.
ORCID-Profile: Laia Nou-Fontanet, Carmen Martín-Gómez, Anne-Catherine Bachoud-Lévi, Giovanna Zorzi, Alessandro Capuano, Juan Antonio Blasco-Amaro, Juan Darío Ortigoza-Escobar
Zitieren
APA
Nou-Fontanet, L., Martín-Gómez, C., Isabel-Gómez, R., Bachoud-Lévi, A. C., Zorzi, G., Capuano, A., NKX2-1-Related Disorders Guideline Working Group, Blasco-Amaro, J. A., & Ortigoza-Escobar, J. D. (2023). Systematic review of drug therapy for chorea in NXK2 ‐1‐related disorders: Efficacy and safety evidence from case studies and series. European Journal of Neurology. https://doi.org/10.1111/ene.16038
Vancouver
Nou-Fontanet L, Martín-Gómez C, Isabel-Gómez R, Bachoud-Lévi AC, Zorzi G, Capuano A, et al. Systematic review of drug therapy for chorea in NXK2 ‐1‐related disorders: Efficacy and safety evidence from case studies and series. European Journal of Neurology. 2023. doi:10.1111/ene.16038
BibTeX
@article{NouFontanet2023,
author = {Nou-Fontanet, Laia and Martín-Gómez, Carmen and Isabel-Gómez, Rebeca and Bachoud-Lévi, Anne-Catherine and Zorzi, Giovanna and Capuano, Alessandro and NKX2-1-Related Disorders Guideline Working Group, NKX2-1-Related Disorders Guideline Working Group and Blasco-Amaro, Juan Antonio and Ortigoza-Escobar, Juan Darío},
title = {Systematic review of drug therapy for chorea in NXK2 ‐1‐related disorders: Efficacy and safety evidence from case studies and series},
journal = {European Journal of Neurology},
year = {2023},
doi = {10.1111/ene.16038}
}
EUVIMED